FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo

Cancer

Volumn 118, Issue 1, 2012, Pages 134-146

  Fang, Feng ^a   Yang, Lianyue ^a   Tao, Yiming ^a   Qin, Wei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

5 fluorouracil; chemotherapy; doxorubicin; FBI 1; hepatocellular carcinoma; p21; p27; p53; prognosis

Indexed keywords

DOXORUBICIN; FACTOR THAT BINDS TO INDUCER OF SHORT TRANSCRIPTS 1; FLUOROURACIL; MESSENGER RNA; PROTEIN P21; PROTEIN P27; PROTEIN P53; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER RESISTANCE; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 83855162908     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26251     Document Type: Article

References (38)

1. Bosch FX, Ribes J, Diaz M, Cleries R,. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004; 127: S5-S16. (Pubitemid 39423365)
2. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108. (Pubitemid 40372904)
3. Roberts LR,. Sorafenib in liver cancer-just the beginning. N Engl J Med. 2008; 359: 420-422.
4. Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ, Wu F,. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg. 2009; 249: 118-123.
5. Pang RW, Joh JW, Johnson PJ, et al. Biology of hepatocellular carcinoma. Ann Surg Oncol. 2008; 15: 962-971.
6. Wang ZL, Liang P, Dong BW, et al. Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg. 2008; 12: 327-337.
7. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD,. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009; 3: 353-367.
8. Bosch FX, Ribes J, Borras J,. Epidemiology of primary liver cancer. Semin Liver Dis. 1999; 19: 271-285. (Pubitemid 29488770)
9. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer. 2000; 85: 498-502. (Pubitemid 30075127)
10. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z,. Genetic mechanisms of hepatocarcinogenesis. Oncogene. 2002; 21: 2593-2604. (Pubitemid 34438112)
11. Kusano N, Shiraishi K, Kubo K, Oga A, Okita K, Sasaki K,. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology. 1999; 29: 1858-1862. (Pubitemid 29247061)
12. Wu F, Yang LY, Li FY, Ou DP, Chen DP, Fan C,. Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology. 2009; 50: 1839-1850.
13. McKillop IH, Moran DM, Jin X, Koniaris LG,. molecular pathogenesis of hepatocellular carcinoma. J Surg Res. 2006; 136: 125-135. (Pubitemid 44634548)
14. Calvisi DF, Factor VM, Loi R, Thorgeirsson SS,. Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res. 2001; 61: 2085-2091. (Pubitemid 32692031)
15. Pessler F, Pendergrast PS, Hernandez N,. Purification and characterization of FBI-1, a cellular factor that binds to the human immunodeficiency virus type 1 inducer of short transcripts. Mol Cell Biol. 1997; 17: 3786-3798. (Pubitemid 27281853)
16. Aravind L, Koonin EV,. Fold prediction and evolutionary analysis of the POZ domain: structural and evolutionary relationship with the potassium channel tetramerization domain. J Mol Biol. 1999; 285: 1353-1361. (Pubitemid 29060438)
17. Morrison DJ, Pendergrast PS, Stavropoulos P, Colmenares SU, Kobayashi R, Hernandez N,. FBI-1, a factor that binds to the HIV-1 inducer of short transcripts (IST), is a POZ domain protein. Nucleic Acids Res. 1999; 27: 1251-1262. (Pubitemid 29206432)
18. Choi WI, Jeon BN, Yun CO, et al. Proto-oncogene FBI-1 represses transcription of p21CIP1 by inhibition of transcription activation by p 53 and Sp1. J Biol Chem. 2009; 284: 12633-12644.
19. Maeda T, Hobbs RM, Merghoub T, et al. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature. 2005; 433: 278-285.
20. Lee DK, Kang JE, Park HJ, et al. FBI-1 enhances transcription of the nuclear factor-kappaB (NF-kappaB)-responsive E-selectin gene by nuclear localization of the p65 subunit of NF-kappaB. J Biol Chem. 2005; 280: 27783-27791.
21. Jeon BN, Yoo JY, Choi WI, Lee CE, Yoon HG, Hur MW,. Proto-oncogene FBI-1 (Pokemon/ZBTB7A) represses transcription of the tumor suppressor Rb gene via binding competition with Sp1 and recruitment of co-repressors. J Biol Chem. 2008; 283: 33199-33210.
22. Apostolopoulou K, Pateras IS, Evangelou K, et al. Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer. J Pathol. 2007; 213: 294-302. (Pubitemid 350074019)
23. Rovin RA, Winn R,. Pokemon expression in malignant glioma: an application of bioinformatics methods [serial online]. Neurosurg Focus. 2005; 19: E8.
24. Aggarwal A, Hunter WJ 3rd, Aggarwal H, et al. Expression of leukemia/lymphoma-related factor (LRF/POKEMON) in human breast carcinoma and other cancers. Exp Mol Pathol. 2010; 89: 140-148.
25. Wang XM, Yang LY, Guo L, Fan C, Wu F,. p 53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer. 2009; 115: 4554-4563.
26. Yang LY, Tao YM, Ou DP, Wang W, Chang ZG, Wu F,. Increased expression of Wiskott-Aldrich syndrome protein family verprolin-homologous protein 2 correlated with poor prognosis of hepatocellular carcinoma. Clin Cancer Res. 2006; 12: 5673-5679. (Pubitemid 44629594)
27. Wang W, Wu F, Fang F, Tao YM, Yang LY,. Inhibition of invasion and metastasis of hepatocellular carcinoma cells via targeting RhoC in vitro and in vivo. Clin Cancer Res. 2008; 14: 6804-6812.
28. Ou DP, Tao YM, Tang FQ, Yang LY,. The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by up-regulation of matrix metalloproteinases. Int J Cancer. 2007; 120: 1208-1214.
29. Haraguchi N, Ishii H, Mimori K, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010; 120: 3326-3339.
30. Huynh H, Chow PK, Soo KC,. AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther. 2007; 6: 2468-2476. (Pubitemid 47480412)
31. Park JH, Koh KC, Choi MS, et al. Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am J Surg. 2006; 192: 29-33. (Pubitemid 43849602)
32. Shirabe K, Wakiyama S, Gion T, et al. Clinicopathological risk factors linked to recurrence pattern after curative hepatic resection for hepatocellular carcinoma-results of 152 resected cases. Hepatogastroenterology. 2007; 54: 2084-2087.
33. Yachida S, Sakamoto M, Imaida K, et al. p27(Kip1)is overexpressed in very early stages of hepatocarcinogenesis. Cancer Sci. 2008; 99: 2152-2159.
34. Hui AM, Makuuchi M, Li X,. Cell cycle regulators and human hepatocarcinogenesis. Hepatogastroenterology. 1998; 45: 1635-1642. (Pubitemid 28515174)
35. Vousden KH, Lu X,. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002; 2: 594-604. (Pubitemid 37328926)
36. Toledo F, Wahl GM,. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006; 6: 909-923. (Pubitemid 44862676)
37. Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K, Maeda S,. P53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res. 1994; 54: 231-235.
38. Cui J, Meng X, Gao X, Tan G,. Curcumin decreases the expression of Pokemon by suppressing the binding activity of the Sp1 protein in human lung cancer cells. Mol Biol Rep. 2010; 37: 1627-1632.